| 4.63 -0.45 (-8.86%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.36 | 1-year : | 7.43 |
| Resists | First : | 5.44 | Second : | 6.36 |
| Pivot price | 4.36  |
|||
| Supports | First : | 4.39 | Second : | 3.75 |
| MAs | MA(5) : | 4.82 |
MA(20) : | 4.29 |
| MA(100) : | 3.91 |
MA(250) : | 4.15 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 73 |
D(3) : | 80.8 |
| RSI | RSI(14): 58.7 |
|||
| 52-week | High : | 6.01 | Low : | 3.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CING ] has closed below upper band by 31.4%. Bollinger Bands are 86.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.02 - 5.05 | 5.05 - 5.07 |
| Low: | 4.54 - 4.57 | 4.57 - 4.59 |
| Close: | 4.58 - 4.63 | 4.63 - 4.67 |
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Tue, 16 Dec 2025
Cingulate Inc Reinstates Shane Schaffer as CEO - The Globe and Mail
Mon, 15 Dec 2025
Cingulate reinstates Shane Schaffer as CEO, updates employment terms - Investing.com
Mon, 15 Dec 2025
Cingulate Inc Reinstates Shane Schaffer as CEO - TipRanks
Mon, 08 Dec 2025
Ascendiant Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Tue, 18 Nov 2025
Cingulate (NASDAQ: CING) Gains FDA Acceptance of CTx-1301 NDA, Eyes ADHD Launch - Stock Titan
Tue, 18 Nov 2025
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 - TMX Newsfile
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 4.3 (%) |
| Shares Short | 347 (K) |
| Shares Short P.Month | 259 (K) |
| EPS | -2.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -106.7 % |
| Return on Equity (ttm) | -275.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.79 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -1.68 |
| PEG Ratio | 0 |
| Price to Book value | 7.98 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|